Better, faster & safer therapeutic Ab discovery. We are changing the process with AI solutions

MAbSilico

A French deeptech company designing and implementing computational solutions for antibodies and biodrugs discovery and development

About MAbSilico

Revolutionizes antibody discovery

MAbSilico provides a formal embedded AI-technology for antibody discovery, reducing the risks of failure and the duration of discovery and preclinical steps, as well as strengthening intellectual property protection. Conventional approaches for the drug discovery take up to three years, while MAbSilico technologies allow shrinking this time to a few weeks.

Our process & method

Using AI approaches

MAbSilico’s technology is based on 20 years of academic research performed by highly competent scientists. Each methods are calibrated using parameters set up from proprietary databases during the R&D stage, and they are all validated with state-of-the-art experimental assays. Thanks to this combined approaches (computational and biology), MAbSilico can show that the predictive data always converge towards the biological truth.

Our solutions

And a human team

The team is the best combination of computational scientists and biologists. The AI-based technologies are validated and improved in our wet-lab facility to generate a product ready to the market. The team gathers more than 100 scientific publications, and 4 patents. Our onboarded entrepreneur has a cumulative fundraising record of 50 M€ and corporate M&A of 70 M€ while industrial’s KOLs of our scientific advisory board have scientific and market visions.

The Team

In continuous evolution

In 2019, MAbSilico was one of the six winners of the Bpifrance Concours d’innovation i-Nov award in the “Bioproduction” track, a highly competitive grant program hosted by Bpifrance, the French public investment bank. In 2020, MAbSilico joined the NVIDIA Inception program and the Microsoft Azure startup program to accelerate its development.

News & publications

Navigate

47 therapeutics domains: 11 oncology, 3 infectiology, …

148 antibody characterized

23 Clients in 5 countries

MAbSilico SAS

Le HQ

1 impasse du Palais 37000 Tours

FRANCE

contact@mabsilico.com